Lucid Diagnostics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), has announced its participation in two upcoming investor conferences in August 2025.

The company will attend the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference for one-on-one meetings on August 11-12, 2025. Additionally, management will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025, at 2:30 PM ET in Boston, MA. The Canaccord presentation will be available via webcast with a 30-day replay option.

NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that management will participate in the following upcoming investor conferences:

• 10^th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
  • 1x1 Meetings: August 11-12, 2025
  • Location: Virtual

• Canaccord Genuity 45^th Annual Growth Conference
  • Fireside Chat: August 13, 2025, at 2:30 PM ET
  • Location: Boston, MA

The live and archived webcast of the Canaccord Genuity fireside chat can be accessed by clicking here or by visiting the Investor Relations Section of the Lucid Diagnostics website.  A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard^® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck^® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-upcoming-investor-conferences-302521811.html

SOURCE Lucid Diagnostics

FAQ

When is Lucid Diagnostics (LUCD) presenting at the Canaccord Genuity Conference?

Lucid Diagnostics will present a fireside chat at the Canaccord Genuity Conference on August 13, 2025, at 2:30 PM ET in Boston, MA.

How can investors access Lucid Diagnostics' (LUCD) Canaccord Conference presentation?

Investors can access the live and archived webcast through the provided link or by visiting the Investor Relations Section of the Lucid Diagnostics website. A replay will be available for 30 days after the presentation.

Which investor conferences is Lucid Diagnostics (LUCD) attending in August 2025?

Lucid Diagnostics is attending two conferences: the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference (August 11-12) and the Canaccord Genuity 45th Annual Growth Conference (August 13).

What type of company is Lucid Diagnostics (LUCD)?

Lucid Diagnostics is a commercial-stage, cancer prevention medical diagnostics company and operates as a subsidiary of PAVmed Inc. (Nasdaq: PAVM).